natgillin/translations-raw huggingface dataset:
CHMP besluttede derfor, at fordelene ved Bretaris Genuair opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
Therefore, the CHMP decided that Bretaris Genuair’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Buccolam opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Buccolam.
The Committee therefore decided that Buccolam’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Eklira Genuair opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
Therefore, the CHMP decided that Eklira Genuair’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Enurev Breezhaler opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Enurev Breezhaler.
Therefore, the CHMP decided that Enurev Breezhaler’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Eylea opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Eylea.
Therefore, the CHMP decided that Eylea’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Inlyta opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Inlyta.
The CHMP therefore decided that Inlyta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved IONSYS er større end risiciene til behandling af akut, moderat til svær smerte efter operation udelukkende i hospitalsomgivelser.
Therefore, the Committee decided that IONSYS’s benefits are greater than its risks for the management of acute moderate to severe post-operative pain for use in a hospital setting only.
CHMP besluttede derfor, at fordelene ved Jentadueto opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Jentadueto.
Therefore the CHMP decided that Jentadueto’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Komboglyze opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Komboglyze.
The Committee therefore concluded that the benefits of Komboglyze outweigh its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Krystexxa opvejer risicie- ne, og anbefalede udstedelse af en markedsføringstilladelse for Krystexxa.
The CHMP therefore decided that Krystexxa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Perjeta opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Perjeta.
Therefore the CHMP decided that Perjeta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Rasitrio opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Rasitrio.
The Committee therefore decided that Rasitrio’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Revestive opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Revestive.
Therefore, the CHMP decided that Revestive’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Seebri Breezhaler opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Seebri Breezhaler.
Therefore, the CHMP decided that Seebri Breezhaler’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Synflorix opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Synflorix.
The CHMP therefore decided that Synflorix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Tovanor Breezhaler opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Tovanor Breezhaler.
Therefore, the CHMP decided that Tovanor Breezhaler’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede derfor, at fordelene ved Votubia opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Votubia.
The CHMP therefore concluded that the benefits of Votubia outweigh its risks and recommended that it be given marketing authorisation.
CHMP besluttede på baggrund af resultaterne fra undersøgelserne, at fordelene ved Cinryze opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
Based on the evidence from the studies, the CHMP concluded that Cinryze’s benefits are greater than its risks and recommended that it be approved for use in the EU.
CHMP besluttede på grundlag af den foreliggende dokumentation, at fordelene ved Multaq opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Multaq.
Based on the available evidence, the CHMP decided that Multaq’s benefits are greater than its risks and recommended that Multaq be given marketing authorisation.
CHMP besluttede, at Afinitor havde vist sig at hæmme sygdomsprogressionen hos patienter med fremskredne neuroendokrine tumorer med oprindelse i bugspytkirtlen, fremskredent nyrecellekarcinom og hormonreceptorpositiv fremskreden brystkræft.
The CHMP decided that Afinitor was shown to slow down disease progression in patients with advanced neuroendocrine tumours of pancreatic origin, advanced renal cell carcinoma and hormone-receptor- positive advanced breast cancer.
CHMP besluttede, at Aldurazyme er virksomt til at kontrollere symptomerne på MPS I. Udvalget besluttede, at fordelene ved Aldurazyme var større end risiciene, og anbefalede derfor udstedelse af en markedsføringstilladelse for Aldurazyme.
The CHMP decided that Aldurazyme gives effective control of the symptoms of MPS I. The Committee decided that Aldurazyme’s benefits are greater than its risks and recommended that Aldurazyme be given marketing authorisation.
CHMP besluttede, at for patienter med Fabrys sygdom kan behandling med Fabrazyme give kliniske fordele på lang sigt.
The CHMP decided that, for patients with Fabry disease, treatment with Fabrazyme might provide long- term clinical benefits.
CHMP besluttede, at for patienter med Fabrys sygdom kan behandling med Replagal give kliniske fordele på lang sigt.
The CHMP decided that for patients with Fabry disease treatment with Replagal might provide long- term clinical benefits.
CHMP besluttede, at fordelene ved Ablavar er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Ablavar.
The CHMP decided that Ablavar’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Abraxane opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Abraxane.
The Committee decided that Abraxane’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Aclasta opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Aclasta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Actos opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Actos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Actraphane opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Actraphane.
The CHMP decided that Actraphane’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Actrapid opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Actrapid.
The CHMP decided that Actrapid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Adcirca opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Adcirca.
The CHMP decided that Adcirca’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Adrovance opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Adrovance’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Advate opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Advate’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Aerius opvejer risiciene ved lindring af symptomer forbundet med allergisk rhinitis eller urticaria og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Aerius’s benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Aflunov opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Aflunov’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ambirix er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Ambirix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Aprovel opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Aprovel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Aranesp er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Aranesp.
The CHMP decided that Aranesp’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Arava opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Arava.
The CHMP decided that Arava’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Avandamet er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Avandamet.
The CHMP decided that Avandamet’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Avandia er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Avandia.
The CHMP decided that Avandia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Avastin opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Avastin.
The CHMP decided that Avastin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Avonex opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Avonex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Axura opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Axura’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Azilect opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Azilect.
The CHMP decided that Azilect’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Azopt opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Azopt.
The Committee for Medicinal Products for Human Use (CHMP) decided that Azopt’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved BeneFIX er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for BeneFIX.
The CHMP decided that BeneFIX’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Bondenza opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Bondenza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Bondronat opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Bondronat’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Bonviva opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Bonviva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Bridion opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Bridion.
The CHMP decided that Bridion’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Brilique opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Brilique.
The CHMP decided that Brilique’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Byetta opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Byetta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Caelyx opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Caelyx.
The CHMP decided that Caelyx’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Cayston er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Cayston.
The CHMP decided that Cayston’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved CellCept opvejer risiciene og anbefalede udstedelse af en markedsføringstilladelse for CellCept.
The CHMP decided that CellCept’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Celsentri opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Celsentri’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Celvapan opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Celvapan.
The CHMP decided that Celvapan’s benefits of are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Cervarix opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Cervarix.
The CHMP decided that Cervarix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Cetrotide opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Cetrotide.
The CHMP decided that Cetrotide’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Cialis opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Cialis.
The CHMP decided that Cialis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Cimzia opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Cimzia.
The CHMP decided that Cimzia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Clopidogrel Zentiva opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Clopidogrel Zentiva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved CoAprovel opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that CoAprovel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Combivir er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Combivir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Conbriza opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Conbriza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Copalia opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Copalia HCT.
The CHMP therefore decided that Copalia HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Copalia opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Copalia.
The CHMP decided that Copalia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Cubicin opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Cubicin.
The CHMP decided that Cubicin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Cystagon opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Cystagon’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Dacogen opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Dacogen.
The CHMP decided that Dacogen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Dafiro HCT opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Dafiro HCT.
The CHMP therefore decided that Dafiro HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Dafiro opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Dafiro.
The CHMP decided that Dafiro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved DaTSCAN er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for DaTSCAN.
The CHMP decided that DaTSCAN’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Docetaxel Winthrop opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Docetaxel Winthrop’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Doribax opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Doribax’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved DuoTrav opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for DuoTrav.
The CHMP decided that DuoTrav’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Dynastat opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Dynastat’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Ebixa opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Ebixa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Effentora opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Effentora.
The CHMP decided that Effentora’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Efficib opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Efficib’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Eliquis opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Eliquis.
The CHMP decided that the benefits of Eliquis are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved ellaOne opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for ellaOne.
The CHMP decided that ellaOne’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Emend opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Emend.
The CHMP decided that Emend’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Enbrel opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Enbrel.
The CHMP decided that Enbrel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Epivir er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Epivir.
The CHMP decided that Epivir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Erbitux opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
The CHMP decided that Erbitux’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Esmya opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Esmya.
The CHMP concluded that the benefits of Esmya outweigh its risks and recommended that it be granted marketing authorisation.
CHMP besluttede, at fordelene ved Evicel opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Evicel.
The CHMP decided that Evicel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Exforge HCT opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Exforge HCT.
The CHMP therefore decided that Exforge HCT’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Exforge opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse for Exforge.
The CHMP decided that Exforge’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP besluttede, at fordelene ved Exjade opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
The CHMP decided that Exjade’s benefits are greater than its risks and recommended that it be given marketing authorisation.